OncoSil Medical Wins TGA Approval to Sell Its Pancreatic Cancer Device in Australia
OncoSil Medical secures TGA approval for the OncoSil™ device, unlocking Australian commercialisation
OncoSil Medical Limited (ASX: OSL) has received approval from the Australian Therapeutic Goods Administration (TGA) for the OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer (LAPC) in addition to gemcitabine-based chemotherapy. The device has been included on the Australian Register of Therapeutic Goods (ARTG), marking a significant regulatory milestone for the company.
OncoSil™ is the first and only TGA-approved Class III medical device targeting tumours directly within the pancreas, a classification that carries the highest stringency of regulatory review for medical devices. The approval opens the path to commercialisation in Australia, the company’s home market, and is expected to support future regulatory approvals in additional international markets.
Pancreatic cancer is the 8th most common cancer in Australia, with approximately 4,353 new cases diagnosed each year. Access to new treatment options for this disease, which carries limited therapeutic choices and poor survival outcomes, has historically been restricted for Australian patients.
Nigel Lange, CEO & Managing Director, OncoSil Medical
“Receiving TGA approval is a defining moment for OncoSil Medical and an especially proud achievement as an Australian medical technology company. Having developed this innovative treatment platform in Australia, it is incredibly significant to now secure approval in our home market. This milestone not only validates the strength of our clinical and regulatory work but also enables Australian patients suffering from one of the most difficult-to-treat cancers to gain access to a new therapeutic option. We believe this approval will further accelerate clinical adoption and strengthen our global commercialisation strategy.”
When big ASX news breaks, our subscribers know first
Understanding OncoSil™ and the unmet need in pancreatic cancer
What makes pancreatic cancer so difficult to treat?
Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women globally, with approximately 500,000 new cases detected every year. The disease is generally diagnosed at a later stage, which severely limits treatment options and contributes to poor long-term survival outcomes.
“Unresectable locally advanced pancreatic cancer (LAPC)” refers specifically to tumours that cannot be surgically removed, either due to their size or proximity to critical structures. For these patients, treatment options are often constrained to chemotherapy regimens, leaving a substantial unmet clinical need.
How the OncoSil™ device works
The OncoSil™ device delivers targeted radiation directly into the tumour through the intratumoural placement of Phosphorous-32 (32P) Microparticles. This approach enables healthcare professionals to administer a greater radiation dose to the tumour compared to external beam radiotherapy, while sparing surrounding critical organs from unnecessary radiation exposure.
The device carries an established international regulatory footprint, having received CE Marking in both the EU and the UK. It holds breakthrough device designation in both Europe and the United States, and is currently approved for sale in 30+ countries. Commercial treatments using the OncoSil™ device have already been undertaken in:
- Spain
- Italy
- Austria
- Germany
- Greece
- Türkiye
- Portugal
- Israel
- United Kingdom
The next major ASX story will hit our subscribers first
Why this milestone matters for investors and what comes next
A milestone that validates the global commercialisation strategy
The TGA approval functions as a dual catalyst for OncoSil Medical. It opens the Australian market directly and, as noted in the announcement, is expected to strengthen the company’s position when seeking regulatory approvals in additional international markets. Home-market approval for an Australian-developed medical technology carries particular weight in demonstrating regulatory credibility to overseas authorities.
Clinical endorsement from a leading Australian specialist reinforces the significance of the approval for the medical community.
Professor Nam Nguyen, Head of Endoscopy at the Royal Adelaide Hospital and Clinical Professor at Adelaide University
“Pancreatic cancer remains one of the greatest unmet needs in oncology, and the availability of the OncoSil™ device in Australia is an important advancement for clinicians and patients. For Australian patients suffering from locally advanced pancreatic cancer (LAPC), where treatment options are often limited, access to new technologies such as OncoSil™ is particularly important. Based on our extensive experience with the OncoSil™ device, it has demonstrated significant potential value in helping drive patients towards surgical eligibility, which remains one of the most important determinants of long-term outcomes in pancreatic cancer. In addition, the targeted nature of the treatment may provide an important additional survival benefit when integrated into multidisciplinary treatment pathways. TGA approval is a significant milestone that recognises both the innovation and potential clinical value of this therapy.”
The announcement also noted the near-completion of a new manufacturing facility in Macquarie Park, Sydney, developed in partnership with Cyclotek. Management has indicated this facility is expected to strengthen the company’s domestic and global supply chain capabilities as it scales commercial operations.
Key factors supporting the investment case
- OncoSil™ is the first and only TGA-approved Class III medical device targeting tumours directly within the pancreas.
- TGA approval enables commercialisation in Australia, the company’s home market.
- The approval is expected to support additional international regulatory approvals in further markets.
- A new Macquarie Park manufacturing facility, developed with Cyclotek, is nearing completion and is positioned to support domestic and global supply chain requirements.
- Clinical validation is reinforced by expert endorsement from Professor Nam Nguyen and a growing body of clinical evidence accumulated across commercial treatments in nine countries.
| Region / Market | Regulatory Status | Designation | Commercial Treatments | Notes |
|---|---|---|---|---|
| EU / UK | CE Marking approved | Breakthrough device (Europe) | Yes — Spain, Italy, Austria, Germany, Greece, Portugal, UK | Marketing authorisation in both EU and UK |
| United States | Not yet approved for sale | Breakthrough device designation | No | Breakthrough designation granted by FDA |
| Australia | TGA approved; ARTG listed | Class III medical device | Commercialisation now enabled | First and only TGA-approved device targeting tumours within the pancreas |
| Türkiye / Israel | Approved for sale | N/A | Yes — Türkiye, Israel | Part of the 30+ country approvals |
| 30+ countries (total) | Approved for sale | N/A | Yes — multiple markets | Includes EU, UK, Türkiye, Israel, and others |
Don’t Miss the Next Healthcare Breakthrough on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to receive the moment-it-breaks coverage that matters to your portfolio.